17,261 trials
Asthma
Primary: Safety: Relative Change From Baseline* in Forced Expiratory Volume in 1 s (FEV1) -- 15 Min Post-dose — 2.12; 0.26 percent change — p=0.113
Colorectal Neoplasms
Primary: Overall Survival — 8.6; 4.7 months
Liver Cancer
Primary: Number of Participants With Complete Response or Partial Response (Objective Response), as Assessed According Central Review — 22; 22 Participants
Prescription Opiate/Medication Dependence
Primary: Illicit-positive Urines During Treatment and Follow-up — 0; 0; 1; 1 Participants
Non Alcoholic Steatohepatitis
Primary: NAS Score (Nonalcoholic Fatty Liver Disease [NAFLD] Activity Score) — -1.50; -1.86; -1.33 units on a scale — p=0.7689
Covid19
Primary: Change in Activated Partial Thromboplastin Time (APTT) > 1.5 Seconds — 0.95; 1.10 ratio
Juvenile Idiopathic Arthritis
Primary: Maximum Serum Concentration (Cmax) of Sarilumab at Week 12 — 7.57; 13.7; 22.0; 33.6 milligram per liter (mg/L)
Attention-Deficit/Hyperactivity Disorder (ADHD)
Primary: Incidence of Adverse Events During 6 Weeks of Treatment — 88.5; 72.0 percentage of subjects
Metastatic Colorectal Cancer
Primary: Objective Response Rates (RECIST 1.1) — 42.4 Percentage of participants
Glaucoma, Open-Angle · Ocular Hypertension
Primary: Travoprost Free Acid Concentration (ng/mL) in Aqueous Humor 12 Months Post-administration — 5.57 ng/mL
Gastric Cancer · Hepatocellular Carcinoma
Primary: Progression-free Survival — 153.87 Days
Influenza
Primary: Immunogenicity Endpoint: Geometric Mean Titer (GMT) for the A/H1N1, B/Victoria and B/Yamagata Vaccine Strains by Hemagglutination Inhibition (HI) Assay and for A/H3N2…
Nervous System Disorder · Genetic Syndrome
Primary: Mean Change From Baseline in Neurological Symptoms Assessed by Using International Cooperative Ataxia Rating Scale (ICARS) Score - ITT Population — -2.2; -3.4; -4.0…
Aging · Sedentary Lifestyle · Frailty
Primary: Skeletal Muscle Mitochondrial Respiration State 3; Baseline to 12-week Change. — 2.2; -0.8 pmol O2/s/mg DW — p=0.9017
Neuroendocrine Tumors
Primary: Progression Free Survival (PFS) — 34 % of participants with response